ArticleThe open ophthalmology journal2010
Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community.
Article in The open ophthalmology journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Effectiveness of a Newly Developed Instillation Aid for Unit-Dose Ophthalmic Solutions.Journal of clinical medicine · 2025Article
- Article
- Factors associated with achieving intraocular pressure lower than 15 mmHg by Trabectome surgery in primary open-angle glaucoma.Scientific reports · 2021Article
- A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan.International ophthalmology · 2019Article
- Wide Variation of Squeezing Force and Dispensing Time Interval among Eyedropper Bottles.Journal of ophthalmology · 2019Article
- Reduction in Ocular Hypotensive Eyedrops by Ab Interno Trabeculotomy Improves Not Only Ocular Surface Condition But Also Quality of Vision.Journal of ophthalmology · 2018Article
- Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy.Patient preference and adherence · 2018Article
- Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy.Journal of ophthalmology · 2018Article
- Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database.Journal of ophthalmology · 2017Article
- Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost.The open ophthalmology journal · 2016Article
- Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2014Article
- Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2014Article
- Phase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2014Article
- Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy.Japanese journal of ophthalmology · 2012Article
- Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review.Patient preference and adherence · 2011Article
- Drug use in primary open angle glaucoma: a prospective study at a tertiary care teaching hospital.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate changes in the trend of anti-glaucoma ophthalmic solutions in 2000-2008 in a Japanese local community. MATERIALS AND
methodsThe subjects of this study were patients with glaucoma who were registered in the database of the glaucoma clinic of University of Yamanashi Hospital or the database of the Association for Research in Supporting System of Chronic Diseases (ARSSCD). The trend of newly prescribed anti-glaucoma ophthalmic solutions from January 2000 through July 2008 was analyzed. Changes in the trend of anti-glaucoma ophthalmic solutions and the persistence of each anti-glaucoma ophthalmic solution were investigated.
resultsA total of 1,955 glaucoma patients were enrolled. Mean intraocular pressure (IOP) significantly reduced by year (R(2)=0.7938, p<0.001). The number of new prescriptions for analysis in the study period was 7,831. Prostaglandin (PG) analogues accounted for approximately 40% of the prescriptions during the period, and were followed by beta-blockers and carbonic anhydrase inhibitors (CAIs). Those three anti-glaucoma ophthalmic solutions accounted for approximately 90% of all the prescriptions. Latanoprost showed the longest persistence among the anti-glaucoma ophthalmic solutions. The number of newly prescribed anti-glaucoma ophthalmic solutions gradually increased with time.
conclusionsPG analogues are the most frequently prescribed and latanoprost showed the longest persistence among the anti-glaucoma ophthalmic solutions. PG analogues, beta-blockers, and CAIs accounted for the majority of newly prescribed anti-glaucoma ophthalmic solutions. An increase in the number of newly prescribed anti-glaucoma ophthalmic solutions may contribute to further IOP reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.